검색 상세

Genetic Polymorphism of Prostanoid Receptors, CRTH2 and TBXA2R in Aspirin Hypersensitivity

  • 발행기관 아주대학교
  • 지도교수 Hae-Sim Park
  • 발행년도 2010
  • 학위수여년월 2010. 2
  • 학위명 박사
  • 학과 및 전공 일반대학원 의학과
  • 실제URI http://www.dcollection.net/handler/ajou/000000010607
  • 본문언어 영어
  • 저작권 아주대학교 논문은 저작권에 의해 보호받습니다.

초록/요약

- ABSTRACT - Genetic Polymorphism of Prostanoid Receptors, CRTH2 and TBXA2R in Aspirin Hypersensitivity Background and Objective: Aspirin ingestion can induce a wide range of clinically recognized allergic reactions, including aspirin intolerant asthma (AIA), also called aspirin exacerbated respiratory disease (AERD), aspirin-intolerant urticaria/angioedema (AIU), chronic rhinitis, and anaphylaxis. We studied two major aspirin hypersensitivity, AIA and AIAU in an association with prostanoids receptor CRTH2 and TBXA2R. The human CRTH2 gene (official name GPR44) encodes a G protein-coupled chemoattractant receptor molecule which is expressed on Th2 cells including other allergy related cells like eosinophils, basophils and monocytes. Its importance in inflammatory cell activation and recruitment in vitro and in vivo has been continuously reported in several studies. Considering the fact that eosinophilic infiltration is more pronounced in AIA patients than it is in ATA patients, we hypothesized that activation of eosinophils via dysregulation of the CRTH2 gene may play an important role in AIA and may be an important marker of this entity. Therefore, this case control study was designed to determine if variation in the CRTH2 gene confers elevated risk for developing AIA. Human Thromboxane A2 (TBXA2), is another eicosanoid product induced by cyclooxygenase may be as important mediator in aspirin hypersensitivity as it can induce bronchoconstriction and bronchohyperresponsiveness. TBXA2 exerts its action by interacting with the G protein-coupled thromboxane A2 receptor (TBXA2R). Based on previous association of TBXA2R with asthma and atopy, we investigated whether genetic polymorphisms of the TBXA2R gene are associated with AIAU phenotype through a case-control of three study subjects. Materials and Methods: The three studies groups 107 patients with AIA, 115 patients with ATA, and 133 normal healthy controls (NC) were recruited from Ajou University Hospital, Suwon, Korea. We genotyped two polymorphisms of CRTH2 located in front of exon-2 (upstream of the ATG) using a primer extension method and the SNAPshot ddNTP primer extension kit. (Applied Biosystems, Foster City, CA, USA). In case of TBXA2R gene polymorphism, three subject groups (167 patients with AIAU, 316 patients with AICU, and 265 patients with normal controls) were enrolled at Ajou University Hospital in Suwon, Korea. Two polymorphisms of TBXA2R (-4684T>C and 795 T>C) were genotyped using a primer extension method and the SNAPshot ddNTP primer extension kit (Applied Biosystems, Foster City, CA, USA). The functional effect of polymorphism of CRTH2 and TBXA2R were analyzed by luciferase reporter assay, electrophoretic mobility shift assay and ELISA. Results: AIA patients had significantly higher serum eotaxin-2 levels than did those with ATA (p=0.034). A significant difference in the genotype frequencies of CRTH2 -466T>C was detected between AIA and ATA patients (p<0.05). The serum eotaxin-2 level was significantly higher in AIA patients carrying the TT genotype than those with the CT and CC type (p<0.05). In vitro functional study demonstrated that the -466T allele had lower luciferase activity (p<0.001) and lower mRNA expression with higher production of eotaxin-2 (p=0.003) in human lung epithelial cells. EMSA showed that CRTH2 -466T produced a specific band with a higher affinity than CRTH2 -466C had. AIA patients exhibited a significantly higher prevalence of paranasal sinusitis and nasal polyps compared to ATA patients (p<0.001 and p<0.001, respectively). The serum eotaxin-2 level was significantly higher in AIA patients than in ATA patients (p=0.034) in our study, while no difference was noted in the eotaxin-1 level. Furthermore, the genotype frequency of TBXA2R -4684T>C was significantly different AIAU and NC on both co-dominant and recessive analysis models. Specifically, AIAU patients showed a significantly higher frequency of the homozygous TT genotype of TBXA2R -4684T>C compared to NC (p=0.015). In addition, there was significant association of atopy status according to TBXA2R -4684T>C polymorphism. AIAU patients carrying TT genotype showed significantly higher atopy status compared to CT or CC type (p=0.013) but not in AICU patients (P>0.05). In vitro functional study demonstrated that the -4684T allele had lower luciferase activity (p<0.001) in HMC-1 cells. EMSA showed that TBXA2R -4684T produced a specific band with a higher affinity than TBXA2R -4684C. There was a significant difference between AIAU vs. NC with respect to serum Thromboxane B2 production (TXB2). AIAU patients showed a significantly lower TXB2 production compared to patients with NC (p=0.016). Conclusion: These study suggest that genetic variability of prostanoid receptors CRTH2 and TBXA2R may be associated with aspirin hypersensitivity, in particular CRTH2 ?466T allele showed higher frequency and increased serum and cellular eotaxin-2 production through lowering of CRTH2 expression in AIA and TBXA2R -4684T allele showed higher frequency and lowered TXB2 production through lowering of TBXA2R expression in AIAU. __________________________________________________________________________ Key words: aspirin hypersensitivity, respiratory disease, acute urticaria, genetic polymorphism, eosinophils, eotaxin, thromboxane.

more

초록/요약

-&#44397;&#47928;&#50836;&#50557;- &#50500;&#49828;&#54588;&#47536; &#52380;&#49885; &#44284;&#48124;&#49457; &#51656;&#54872;&#50640;&#49436;&#51032; &#54532;&#47196;&#49828;&#53440;&#45432;&#51060;&#46300; &#49688;&#50857;&#52404;&#51064; CRTH2&#50752; TBXA2R&#51032; &#50976;&#51204;&#51088; &#45796;&#54805;&#49457; &#50672;&#44396; &#50500;&#51452;&#45824;&#54617;&#44368; &#45824;&#54617;&#50896; &#51032;&#54617;&#44284; &#45208;&#48120; &#49800;&#47112;&#49828;&#53552; &#54036;&#47532;&#52992; (&#51648;&#46020;&#44368;&#49688;:&#48149; &#54644; &#49900;) &#50672;&#44396;&#48176;&#44221; &#48143; &#47785;&#51201;: &#50500;&#49828;&#54588;&#47536; &#48373;&#50857;&#51008; &#51068;&#48512; &#49324;&#46988;&#46308;&#51032; &#44221;&#50864; &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457; &#52380;&#49885;, &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457; &#46160;&#46300;&#47084;&#44592;, &#47564;&#49457; &#48708;&#50684;, &#50500;&#45208;&#54596;&#46973;&#49884;&#49828; &#44057;&#51008; &#45796;&#50577;&#54620; &#50508;&#47112;&#47476;&#44592; &#48152;&#51025;&#51012; &#50976;&#48156;&#54616;&#44592;&#46020; &#54620;&#45796;. &#48376; &#50672;&#44396;&#45716; &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457;&#51004;&#47196; &#45208;&#53440;&#45208;&#45716; &#45824;&#54364;&#51201;&#51064; &#46160; &#51656;&#54872;&#51064; &#44284;&#48124;&#49457; &#52380;&#49885;&#44284; &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457; &#46160;&#46300;&#47084;&#44592;&#50640;&#49436; &#54532;&#47196;&#49828;&#53440;&#44544;&#46976;&#46360; D2 &#49688;&#50857;&#52404;, CRTH2,&#50752; &#54532;&#47196;&#49828;&#53440;&#45432;&#51060;&#46300; &#49688;&#50857;&#52404;, TBXA2R &#50976;&#51204;&#51088;&#46308;&#50640; &#45824;&#54620; &#50976;&#51204;&#52404; &#50672;&#44396;&#51060;&#45796;. &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457; &#52380;&#49885; &#54872;&#51088;&#50640;&#49436; &#54840;&#49328;&#44396; &#50684;&#51613; &#48143; &#50976;&#51077;&#51060; &#50500;&#49828;&#54588;&#47536; &#45236;&#49457; &#52380;&#49885; &#54872;&#51088;&#50640; &#48708;&#54644; &#46160;&#46300;&#47084;&#51648;&#44172; &#45208;&#53440;&#45224;&#51012; &#44256;&#47140;&#54644; &#48380;&#46412;, &#54532;&#47196;&#49828;&#53440;&#44544;&#46976;&#46360; D2 &#49688;&#50857;&#52404;&#51064; CRTH2 &#50976;&#51204;&#51088;&#51032; &#50976;&#51204;&#51088; &#45796;&#54805;&#49457;&#50640; &#46384;&#47480; &#44592;&#45733;&#51201; &#48320;&#54868;&#47484; &#53685;&#54620; &#54840;&#49328;&#44396;&#51032; &#54876;&#49457;&#54868;&#44032; &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457; &#52380;&#49885;&#51032; &#48337;&#51064;&#44592;&#51204;&#50640; &#51473;&#50836;&#54620; &#50669;&#54624;&#51012; &#45812;&#45817;&#54624; &#44163;&#51004;&#47196; &#44032;&#51221;&#54616;&#44256; CRTH2 &#50976;&#51204;&#51088;&#51032; &#50976;&#51204;&#51088; &#45796;&#54805;&#49457; &#51312;&#49324; &#48143; &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457; &#52380;&#49885;&#44284;&#51032; &#50672;&#44288;&#49457; &#50672;&#44396;&#47484; &#49688;&#54665;&#54616;&#50688;&#45796;. &#45908;&#50865;&#51060;, &#52380;&#49885; &#48143; &#50500;&#53664;&#54588;&#50752;&#51032; &#50672;&#44288;&#49457;&#51060; &#48372;&#44256;&#46108; TBXA2R &#50976;&#51204;&#51088;&#51032; &#44221;&#50864;, &#44536; &#50976;&#51204;&#51088;&#51032; &#50976;&#51204;&#51088; &#45796;&#54805;&#49457;&#50640; &#46384;&#47480; &#44592;&#45733; &#48320;&#54868;&#44032; &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457; &#46160;&#46300;&#47084;&#44592;&#51032; &#48337;&#51064;&#44592;&#51204;&#44284; &#44288;&#47144;&#46104;&#45716;&#51648;&#47484; &#50976;&#51204;&#51088; &#50672;&#44288;&#49457; &#50672;&#44396;&#47196; &#51312;&#49324;&#54616;&#50688;&#45796;. &#51116;&#47308; &#48143; &#48169;&#48277;: &#48376; &#50672;&#44396;&#45716; &#50500;&#51452;&#45824; &#48337;&#50896;&#50640; &#45236;&#50896;&#54620; 107&#47749;&#51032; &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457; &#52380;&#49885; &#54872;&#51088;, 115&#47749;&#51032; &#50500;&#49828;&#54588;&#47536; &#45236;&#49457; &#52380;&#49885; &#54872;&#51088;, &#44536;&#47532;&#44256; 133&#47749;&#51032; &#51221;&#49345;&#45824;&#51312;&#44400;&#51012; &#45824;&#49345;&#51004;&#47196; CRTH2 &#50976;&#51204;&#51088;&#51032; &#50976;&#51204;&#51088; &#45796;&#54805;&#49457; &#51312;&#49324; &#48143; &#50672;&#44288;&#49457; &#50672;&#44396;&#47484; &#49688;&#54665;&#54616;&#50688;&#45796;. TBXA2R &#50976;&#51204;&#51088;&#51032; &#44221;&#50864;, &#50500;&#51452;&#45824; &#48337;&#50896;&#50640; &#45236;&#50896;&#54620; 167&#47749;&#51032; &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457; &#44553;&#49457; &#46160;&#46300;&#47084;&#44592; &#54872;&#51088;, 316&#47749;&#51032; &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457; &#47564;&#49457; &#46160;&#46300;&#47084;&#44592; &#54872;&#51088;, &#44536;&#47532;&#44256; 265&#47749;&#51032; &#51221;&#49345;&#45824;&#51312;&#44400;&#51012; &#45824;&#49345;&#51004;&#47196; &#49688;&#54665;&#54616;&#50688;&#45796;. &#46160; &#50976;&#51204;&#51088;&#51032; &#50976;&#51204;&#54805;&#51008; SNAPshot ddNTP primer extention &#53412;&#53944;&#47484; &#49324;&#50857;&#54616;&#50668; &#44208;&#51221;&#46104;&#50632;&#45796;. &#46160; &#50976;&#51204;&#51088;&#51032; &#50976;&#51204;&#51088; &#45796;&#54805;&#49457;&#50640; &#46384;&#47480; &#44592;&#45733; &#48320;&#54872; &#50672;&#44396;&#45716; luciferase reporter assay&#50752; electrophoretic mobility shift assay&#47196; &#49688;&#54665;&#54616;&#50688;&#45796;. &#44208;&#44284;: &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457; &#52380;&#49885; &#54872;&#51088;&#44400;&#50640;&#49436; &#50500;&#49828;&#54588;&#47536; &#45236;&#49457; &#52380;&#49885; &#54872;&#51088;&#44400;&#50640; &#48708;&#54644; &#45458;&#51008; eotaxin-2 &#49373;&#49457;&#51060; &#44288;&#52272;&#46104;&#50632;&#45796; (p=0.034). &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457; &#52380;&#49885; &#54872;&#51088;&#44400;&#44284; &#50500;&#49828;&#54588;&#47536; &#45236;&#49457; &#52380;&#49885; &#54872;&#51088;&#44400;&#50640;&#49436; CRTH2 -466T>C &#50976;&#51204;&#51088; &#45796;&#54805;&#49457;&#51032; &#45824;&#47549;&#50976;&#51204;&#51088; &#48712;&#46020;&#51032; &#52264;&#51060;&#44032; &#53685;&#44228;&#51201;&#51004;&#47196; &#50976;&#51032;&#54616;&#44172; &#44288;&#52272;&#46104;&#50632;&#45796; (p<0.05). &#46608;&#54620;, &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457; &#52380;&#49885; &#54872;&#51088;&#44400;&#50640;&#49436;, CRTH2 -466TT &#50976;&#51204;&#51088;&#54805;&#51012; &#44032;&#51652; &#54872;&#51088;&#46308;&#51032; &#44221;&#50864; -466CT &#46608;&#45716; -466CC &#50976;&#51204;&#51088;&#54805;&#51012; &#44032;&#51652; &#54872;&#51088;&#46308; &#48372;&#45796; &#54792;&#52397; eotaxin-2 &#49373;&#49457;&#51060; &#45458;&#44172; &#44288;&#52272;&#46104;&#50632;&#45796;. &#51064;&#44036; &#54224; &#49345;&#54588;&#49464;&#54252;&#47484; &#51060;&#50857;&#54620; &#49884;&#54744;&#44288;&#45236; &#44592;&#45733; &#50672;&#44396;&#47484; &#53685;&#54644; -466T &#45824;&#47549;&#50976;&#51204;&#51088;&#45716; &#45230;&#51008; luciferase activity&#47484; &#48372;&#50688;&#44256;(p<0.001), &#45230;&#51008; mRNA &#48156;&#54788;&#51012; &#48372;&#51060;&#44256;, &#48152;&#47732; &#45458;&#51008; eotaxin-2 &#49373;&#49457;&#51060; &#44288;&#52272;&#46104;&#50632;&#45796;(p=0.003). EMSA &#49892;&#54744;&#51012; &#53685;&#54644;, -466T &#45824;&#47549;&#50976;&#51204;&#51088;&#50640; -466C &#45824;&#47549;&#50976;&#51204;&#51088;&#48372;&#45796; &#45908; &#45458;&#51008; &#52828;&#54868;&#46020;&#47484; &#44032;&#51648;&#44256; &#44208;&#54633;&#54616;&#45716; &#51204;&#49324;&#51064;&#51088;&#47484; &#54869;&#51064;&#54616;&#50688;&#45796;. TBXA2R -4684T>C &#50976;&#51204;&#51088; &#45796;&#54805;&#49457;&#51032; &#45824;&#47549;&#50976;&#51204;&#51088; &#48712;&#46020;&#51032; &#52264;&#51060;&#45716; &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457; &#44553;&#49457; &#46160;&#46300;&#47084;&#44592; &#54872;&#51088;&#44400;&#44284; &#51221;&#49345; &#45824;&#51312;&#44400;&#50640;&#49436; &#53685;&#44228;&#51201;&#51004;&#47196; &#50976;&#51032;&#54616;&#44172; &#44288;&#52272;&#46104;&#50632;&#45796; (p= 0.015). &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457; &#44553;&#49457; &#46160;&#46300;&#47084;&#44592; &#54872;&#51088;&#44400;&#50640;&#49436;, TBXA2R -4684T>C &#50976;&#51204;&#51088; &#45796;&#54805;&#49457;&#51008; &#50500;&#53664;&#54588;&#50752; &#50672;&#44288;&#49457;(p= 0.013)&#51012; &#48372;&#50688;&#51648;&#47564;, &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457; &#47564;&#49457; &#46160;&#46300;&#47084;&#44592; &#54872;&#51088;&#44400;&#50640;&#49436;&#45716; &#50500;&#53664;&#54588;&#50752; &#50672;&#44288;&#49457;&#51012; &#48372;&#51060;&#51648; &#50506;&#50520;&#45796;. &#51064;&#44036; &#48708;&#48152; &#49464;&#54252;&#51452;&#51064; HMC-1&#51012; &#51060;&#50857;&#54620; &#49884;&#54744;&#44288;&#45236; &#44592;&#45733; &#50672;&#44396;&#47484; &#53685;&#54644; TBXA2R -4684T &#45824;&#47549;&#50976;&#51204;&#51088;&#45716; &#45230;&#51008; luciferase activity&#47484; &#48372;&#50688;&#44256;, EMSA &#49892;&#54744;&#51012; &#53685;&#54644; -4684T &#45824;&#47549;&#50976;&#51204;&#51088;&#50640; -4684C &#45824;&#47549;&#50976;&#51204;&#51088;&#48372;&#45796; &#45908; &#45458;&#51008; &#52828;&#54868;&#46020;&#47484; &#44032;&#51648;&#44256; &#44208;&#54633;&#54616;&#45716; &#51204;&#49324;&#51064;&#51088;&#47484; &#54869;&#51064;&#54616;&#50688;&#45796;. &#46608;&#54620;, &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457; &#44553;&#49457; &#46160;&#46300;&#47084;&#44592; &#54872;&#51088;&#46308;&#51008; &#51221;&#49345; &#45824;&#51312;&#44400;&#50640; &#48708;&#54644; &#45230;&#51008; thromboxane B2 &#49373;&#49457;&#51012; &#48372;&#50688;&#45796; (p=0.016). &#44208;&#47200;: &#48376; &#50672;&#44396;&#47484; &#53685;&#54644;, &#54532;&#47196;&#49828;&#53440;&#44544;&#46976;&#46360; D2 &#49688;&#50857;&#52404;, CRTH2,&#50752; &#54532;&#47196;&#49828;&#53440;&#45432;&#51060;&#46300; &#49688;&#50857;&#52404;, TBXA2R &#50976;&#51204;&#51088;&#46308;&#51032; &#50976;&#51204;&#51088; &#45796;&#54805;&#49457;&#46308;&#51060; &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457;&#44284; &#50672;&#44288;&#49457;&#51060; &#51080;&#51004;&#47728;, &#53945;&#55176; CRTH2 &#50976;&#51204;&#51088;&#45716; &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457; &#52380;&#49885;&#44284; TBXA2R &#50976;&#51204;&#51088;&#45716; &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457; &#44553;&#49457; &#46160;&#46300;&#47084;&#44592;&#50752; &#50672;&#44288;&#49457;&#51060; &#51080;&#51020;&#51012; &#54869;&#51064;&#54616;&#50688;&#45796;. &#54645;&#49900;&#50612;: &#50500;&#49828;&#54588;&#47536; &#44284;&#48124;&#49457;, &#52380;&#49885;, &#44553;&#49457; &#46160;&#46300;&#47084;&#44592;, &#50976;&#51204;&#51088; &#45796;&#54805;&#49457;, &#54840;&#49328;&#44396;

more

목차


TABLE OF CONTENTS
ACKNOWLEDGEMENT I
ABSTRACT II
TABLE OF CONTENTS VI
LIST OF FIGURES IX
LIST OF TABLES XI
ABBREVIATIONS XII
PART-I 1
GENETIC POLYMORPHISM OF CRTH2 IN ASPIRIN INTOLERANT ASTHMA 1
I.INTRODUCTION 2
II. MATERIALS AND METHODS 5
A. Study subjects and phenotyping 5
B. SNP identification and genotyping 6
C. Statistical analysis 7
D. In vivo functional study of CRTH2 -466T>C by measurement of eotaxin-1 and eotaxin-2 using enzyme-linked immunosorbent assay 7
E. Preparation of the CRTH2 construct and dual luciferase assay 8
F. Nuclear extract preparation and electrophoretic mobility shift assay 10
G. Preparation of CRTH2-coding sequence (CDS) (-466T or -466C) and in vitro functional study of eotaxin-2 production in A549 cells and mRNA expression 11
III. RESULTS 13
A. Clinical characteristics of the CRTH2 study subjects 13
B. Genotype and allele frequencies of the CRTH2 gene with the AIA phenotype 15
C. Eotaxin level according to the CRTH2 gene polymorphism 18
D. Eotaxin-2 level according to severity of AIA patients based on classification of FEV1 (%) 18
E. Endogenous expression of CRTH2 from various cell lines 20
F. Dual luciferase activity of CRTH2 -466T>C polymorphism 21
G. Effects of CRTH2 -466T>C gene polymorphisms on
transcriptional activity 22
H. CRTH2 expression and in vitro production of eotaxin-2 from CRTH2 transfected A549 cells 23
IV. DISCUSSION 31
PART-II 35
GENETIC POLYMORPHISM OF TBXA2R IN ASPIRIN INTOLERANT ACUTE URTICARIA 35
I. INTRODUCTION 36
II. MATERIALS AND METHODS 39
A. Study subjects and phenotyping 39
B. SNP identification and genotyping 40
C. Statistical analysis 40
D. Preparation of the TBXA2R construct and dual luciferase assay 41
E. Electrophoretic mobility shift assay 42
F. In vivo measurement of TXB2 production from sera of AIAU and NC 43
III. RESULTS 45
A. Clinical characteristics of the TBXA2R study subjects in AIAU 45
B. Genotype and allele frequencies of the TBXA2R gene with the AIAU phenotype 45
C. Dual luciferase activity of TBXA2R -4684T>C polymorphism 50
D. TBXA2R -4684T>C gene polymorphisms on transcriptional activity 50
E. TXB2 production according to TBXA2R -4684T>C gene polymorphism 56
IV. DISCUSSION 57
V. CONCLUSION 60
REFERENCES 61
국문요약 70


more